Five Prime Therapeutics Inc
Afucosylated anti-FGFR2IIIB antibodies
Last updated:
Abstract:
The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Status:
Grant
Type:
Utility
Filling date:
6 Nov 2018
Issue date:
1 Feb 2022